tbuckley/cabot-search huggingface dataset:
How can hospitals change practice to better implement smoking cessation interventions? A systematic review
Authors: Anna Ugalde, Victoria White, Nicole M. Rankin, Christine Paul, Catherine Segan, Sanchia Aranda, Anna Wong Shee, Alison M. Hutchinson, Patricia M. Livingston
Journal: CA A Cancer Journal for Clinicians (2021)

Abstract Smoking cessation reduces the risk of death, improves recovery, and reduces the risk of hospital readmission. Evidence and policy support hospital admission as an ideal time to deliver smoking‐cessation interventions. However, this is not well implemented in practice. In this systematic review, the authors summarize the literature on smoking‐cessation implementation strategies and evaluate their success to guide the implementation of best‐practice smoking interventions into hospital settings. The CINAHL Complete, Embase, MEDLINE Complete, and PsycInfo databases were searched using terms associated with the following topics: smoking cessation , hospitals , and implementation . In total, 14,287 original records were identified and screened, resulting in 63 eligible articles from 56 studies. Data were extracted on the study characteristics, implementation strategies, and implementation outcomes. Implementation outcomes were guided by Proctor and colleagues' framework and included acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration, and sustainability. The findings demonstrate that studies predominantly focused on the training of staff to achieve implementation. Brief implementation approaches using a small number of implementation strategies were less successful and poorly sustained compared with well resourced and multicomponent approaches. Although brief implementation approaches may be viewed as advantageous because they are less resource‐intensive, their capacity to change practice in a sustained way lacks evidence. Attempts to change clinician behavior or introduce new models of care are challenging in a short time frame, and implementation efforts should be designed for long‐term success. There is a need to embrace strategic, well planned implementation approaches to embed smoking‐cessation interventions into hospitals and to reap and sustain the benefits for people who smoke.
Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma
Authors: Alina Varabyeva, Jens Hillengass, Wenyan Ji, Han Yu, McKenna Butler, Eugene Przespolewski
Journal: Blood (2021)
Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT
Authors: Vivek Patel, Myriam Labopin, Thomas Schroeder, Igor Wolfgang Blau, Lars Klingen Gjaerde, Mahmoud Aljurf, Gérard Socié, Urpu Salmenniemi, Wolfgang A Bethge, Jakob Passweg, Marie Balsat, Emma Nicholson, Johanna Tischer, Sebastian Giebel, Zinaida Peric, Eolia Brissot, Bhagirathbhai Dholaria, Bipin B. Savani, Arnon Nagler, Mohamad Mohty
Journal: Blood (2021)
TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma
Authors: Claudia Manriquez Roman, Michelle J. Cox, Reona Sakemura, Kun Yun, Mohamad M. Adada, Elizabeth L. Siegler, Olivia Sirpilla, Erin E. Tapper, Carli M. Stewart, Ekene J. Ogbodo, Ismail Can, Kendall J. Schick, Evandro D. Bezerra, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Wei Ding, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Gloria Olivier, Nathalie Scholler, Adrian Bot, Mike Mattie, Jenny J. Kim, Simone Filosto, Saad S. Kenderian
Journal: Blood (2021)
Antibody-array interaction mapping: a new method for studying protein-protein interactions and its application to the study of sera from pancreatic cancer patients
Authors: Derek Bergsma, Songming Chen, Yi-Mi Wu, Randall Brand, Brian Haab
Journal: Cancer Research (2007)

3832  Protein-protein interactions are major determinants of protein function, regulation and activity, and alterations in certain interactions can play roles in cancer pathology. A more thorough characterization of protein-protein interactions associated with disease could lead to improved diagnostic methods or treatment strategies. We present a new method for probing and measuring protein-protein interactions, called antibody-array interaction mapping (AAIM), which allows the efficient and sensitive measurement of interactions among a set of proteins in biological samples. A native, non-denatured biological sample, such as a serum sample, is incubated on replicate arrays of multiple antibodies, and after washing away unbound proteins, each array is probed with a different detection antibody, each antibody matched to one of the capture antibodies on the arrays. The binding patterns of the detection antibodies reveal interactions between the targets of the capture antibodies and the targets of the detection antibodies. The method is practical, rapid, and highly sensitive, and it can be used with native, biological samples, so that complex, multi-protein associations can be seen that would be missed with pairwise studies on purified proteins. Further, by using actual biological samples, one can view the real state of an interaction to assess its level in certain situations, which allows a better evaluation of the biological roles of interactions. The application of the method has revealed previously-uncharacterized interactions among cytokines, inflammatory mediators, and various glycoproteins in the sera of pancreatic cancer patients. Immuno-precipitation followed by western blot or mass spectrometry was used to validate two of the interactions, and others are currently under study. The measurement of these interactions in pools of sera from either pancreatic cancer patients or healthy control subjects shows that the levels of interactions between CRP and kininogen and between a CEA family member and IL-1beta may be associated with cancer. Since cytokine signaling and inflammatory processes play critical roles in processes that mediate cancer progression, the newly-observed interactions among inflammatory proteins could be involved in the regulation and control of these processes. Further, the measurement of the levels of certain interactions may prove valuable as a biomarker for certain disease states. Ongoing studies are aimed at further characterizing protein-protein interactions in serum and assessing the diagnostic potential and mechanistic implications of the interactions.
Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in <i>TP53</i>-Mutant Acute Myeloid Leukemia (AML)
Authors: Guillermo Garcia-Manero, Aaron D Goldberg, Eric S. Winer, Jessica K. Altman, Amir T. Fathi, Olatoyosi Odenike, Gail J. Roboz, Phillip Gallacher, Anders Wennborg, Denice Kaylor Hickman, Eyal C. Attar, David A. Sallman
Journal: Blood (2021)
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer
Authors: Lauren C. Shapiro, Astha Thakkar, Sean T. Campbell, Stefanie K. Forest, Kith Pradhan, Jesus D. Gonzalez-Lugo, Ryann Quinn, Tushar D. Bhagat, Gaurav S. Choudhary, Margaret McCort, R. Alejandro Sica, Mendel Goldfinger, Swati Goel, Jesus D. Anampa, David Levitz, Ariel Fromowitz, Akash Pradip Shah, Charlotte Sklow, Gregory Alfieri, Andrew Racine, Lucia Wolgast, Lee Greenberger, Amit Verma, Balazs Halmos
Journal: Cancer Cell (2021)
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
Authors: Kuan-Ying A. Huang, Daming Zhou, Tiong Kit Tan, Charles Chen, Helen M. E. Duyvesteyn, Yuguang Zhao, Helen M. Ginn, Ling Qin, Pramila Rijal, Lisa Schimanski, Robert Donat, Adam Harding, Javier Gilbert-Jaramillo, William James, Julia A. Tree, Karen Buttigieg, Miles Carroll, Sue Charlton, Chia-En Lien, Meei-Yun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, Xiaorui Chen, Tzou-Yien Lin, Elizabeth E. Fry, Jingshan Ren, Che Ma, Alain R. Townsend, David I. Stuart
Journal: Theranostics (2021)

Background: Administration of potent anti-receptor-binding domain (RBD) monoclonal antibodies has been shown to curtail viral shedding and reduce hospitalization in patients with SARS-CoV-2 infection.However, the structure-function analysis of potent human anti-RBD monoclonal antibodies and its links to the formulation of antibody cocktails remains largely elusive.Methods: Previously, we isolated a panel of neutralizing anti-RBD monoclonal antibodies from convalescent patients and showed their neutralization efficacy in vitro.Here, we elucidate the mechanism of action of antibodies and dissect antibodies at the epitope level, which leads to a formation of a potent antibody cocktail.Results: We found that representative antibodies which target non-overlapping epitopes are effective against wild type virus and recently emerging variants of concern, whilst being encoded by antibody genes with few somatic mutations.Neutralization is associated with the inhibition of binding of viral RBD to ACE2 and possibly of the subsequent fusion process.Structural analysis of representative antibodies, by cryo-electron microscopy and crystallography, reveals that they have some unique aspects that are of potential value while sharing some features in common with previously reported neutralizing monoclonal antibodies.For instance, one has a common VH 3-53 public variable region yet is unusually resilient to mutation at residue 501 of the RBD.We evaluate the in vivo efficacy of an antibody cocktail consisting of two potent non-competing anti-RBD antibodies in a Syrian hamster model.We demonstrate that the cocktail prevents weight loss, reduces lung viral load and attenuates pulmonary inflammation in hamsters in both prophylactic and therapeutic settings.Although neutralization of one of these antibodies is IvyspringInternational Publisher abrogated by the mutations of variant B.1.351, it is also possible to produce a bi-valent cocktail of antibodies both of which are resilient to variants B.1.1.7,B.1.351and B.1.617.2.Conclusions: These findings support the up-to-date and rational design of an anti-RBD antibody cocktail as a therapeutic candidate against COVID-19.
Abstract 9163: Demographic Differences in Hypertension and Its Treatment in Malawi
Authors: Saate S Shakil, Alison J Price, Gregory A Roth, Amelia Crampin, Owen Nkoka, Chifundo Kanjala
Journal: Circulation (2021)

Background: Hypertension (HTN), a strong risk factor for cardiovascular disease (CVD), is highly prevalent in Sub-Saharan Africa. Health system interventions targeting demographic determinants of diagnosis and treatment may reduce downstream CVD burden. We investigated age, sex, and location-specific differences in HTN diagnosis and treatment in Malawi. Methods: We examined population-based household survey data (2013 - 2017) from the Malawi Epidemiology and Intervention Research Unit of 30,575 adults &gt; 18 years with self-reported HTN diagnosis/treatment status and resting blood pressure measurements using standardized protocols. We used logistic regression to explore associations between demographic variables (age, sex, rural/urban location) and two outcomes: (1) measured HTN (defined as SBP &gt; 130 mmHg, regardless of diagnosis/treatment status), and (2) treatment for previously diagnosed HTN. Results: The overall prevalence of diagnosed and undiagnosed HTN was 9% and 19.6%, respectively; 45.4% of those previously diagnosed were on antihypertensive treatment. The probability of measured HTN regardless of treatment for those aged &gt;65 years was 80.8% (95% CI 79.1 - 82.5) and 66.5% (64.0 - 68.9) for urban women and men, respectively, and 65.6% (63.5 - 67.7) and 52.2% (49.7 - 54.7) for rural women and men, respectively. Among those with previously diagnosed HTN, probability of treatment was higher in older age groups, but did not differ between locations. Conclusions: We observed a high prevalence of undiagnosed HTN among rural- and urban-dwelling Malawians; over half of those reporting a diagnosis were untreated. Probability of measured HTN varied by sex and location, but probability of treatment did not. Population-level interventions that account for these patterns are needed in both rural and urban settings to increase effective HTN treatment coverage.
Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study
Authors: Patricia Baltasar, María José Terol, Juan Marquet Palomanes, Angel Ramírez Payer, Carol Moreno, Santiago Osorio, Fátima De la Cruz, Jose A. Garcia-Marco, Macarena Ortiz, Eduardo Ríos Herranz, Laura Magnano, Sandra Iraheta, Jose Manuel Puerta, Javier de la Serna, Alicia Smucler Simonovich, Jose Maria Arguiñano, Javier Loscertales, Begoña Muiña, Ruben Fernandez, Tomas García, José A. Márquez, Ana Muntañola Prat, Ernesto Pérez Persona, Lucrecia Yáñez, Manuel Pérez-Encinas, Marcos González Díaz, Gonzalo Caballero, María Angeles Andreu, Rafael Andreu, Ana Ruiz-Zorrilla, Diana Moreno, Christelle Ferrà
Journal: Blood (2021)
Gustav Klimt’s <i>The Kiss—</i>Art and the Biology of Early Human Development
Authors: Dai Hyun Kim, Hyunmi Park, Im Joo Rhyu
Journal: JAMA (2021)

This Arts and Medicine feature identifies biological illustrations that may have influenced ornamental forms in The Kiss and other paintings by Gustav Klimt, emerging from the artist's close interactions with scientists and embryologists and their writings in turn-of-the-century Vienna society.
Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study
Authors: Hajra Okhai, Shema Tariq, Fiona Burns, Yvonne Gilleece, Rageshri Dhairyawan, Teresa Hill, Helen Peters, Claire Thorne, Caroline A Sabin, Jonathan Ainsworth, Sris Allan, Jane Anderson, Ade Apoola, David Chadwick, Duncan Churchill, Valerie Delpech, David Dunn, Ian Fairley, Ashini Fox, Richard Gilson, Mark Gompels, Phillip Hay, Rajesh Hembrom, Teresa Hill, Margaret Johnson, Sophie Jose, Stephen Kegg, Clifford Leen, Dushyant Mital, Mark Nelson, Hajra Okhai, Chloe Orkin, Adrian Palfreeman, Andrew Phillips, Deenan Pillay, Ashley Price, Frank Post, Jillian Pritchard, Caroline Sabin, Achim Schwenk, Anjum Tariq, Roy Trevelion, Andy Ustianowski, John Walsh
Journal: The Lancet HIV (2021)
Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction
Authors: Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini
Journal: Blood (2021)
Analysis of the ISIC image datasets: Usage, benchmarks and recommendations
Authors: Bill Cassidy, Connah Kendrick, Andrzej Brodzicki, Joanna Jaworek-Korjakowska, Moi Hoon Yap
Journal: Medical Image Analysis (2021)

The International Skin Imaging Collaboration (ISIC) datasets have become a leading repository for researchers in machine learning for medical image analysis, especially in the field of skin cancer detection and malignancy assessment. They contain tens of thousands of dermoscopic photographs together with gold-standard lesion diagnosis metadata. The associated yearly challenges have resulted in major contributions to the field, with papers reporting measures well in excess of human experts. Skin cancers can be divided into two major groups - melanoma and non-melanoma. Although less prevalent, melanoma is considered to be more serious as it can quickly spread to other organs if not treated at an early stage. In this paper, we summarise the usage of the ISIC dataset images and present an analysis of yearly releases over a period of 2016 - 2020. Our analysis found a significant number of duplicate images, both within and between the datasets. Additionally, we also noted duplicates spread across testing and training sets. Due to these irregularities, we propose a duplicate removal strategy and recommend a curated dataset for researchers to use when working on ISIC datasets. Given that ISIC 2020 focused on melanoma classification, we conduct experiments to provide benchmark results on the ISIC 2020 test set, with additional analysis on the smaller ISIC 2017 test set. Testing was completed following the application of our duplicate removal strategy and an additional data balancing step. As a result of removing 14,310 duplicate images from the training set, our benchmark results show good levels of melanoma prediction with an AUC of 0.80 for the best performing model. As our aim was not to maximise network performance, we did not include additional steps in our experiments. Finally, we provide recommendations for future research by highlighting irregularities that may present research challenges. A list of image files with reference to the original ISIC dataset sources for the recommended curated training set will be shared on our GitHub repository (available at www.github.com/mmu-dermatology-research/isic_duplicate_removal_strategy).
Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
Authors: Hareth Nahi, Saad Z. Usmani, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Philippe Moreau, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Andrew Farnsworth, Ajai Chari
Journal: Blood (2021)
Blue Pigmentation of the Skin, Sclera, and Teeth
Authors: Nina A. Ran, Matthew L. Hedberg, Misha Rosenbach
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial
Authors: Aurélien Mazeraud, Matthieu Jamme, Rossella Letizia Mancusi, Claire Latroche, Bruno Megarbane, Shidasp Siami, Jonathan Zarka, Guy Moneger, Francesco Santoli, Laurent Argaud, Patrick Chillet, Gregoire Muller, Cedric Bruel, Pierre Asfar, Francois Beloncle, Jean Reignier, Christophe Vinsonneau, Caroline Schimpf, Julien Amour, Cyril Goulenok, Caroline Lemaitre, Benjamin Rohaut, Philippe Mateu, Stephane De Rudnicki, Bruno Mourvillier, Pierre-Louis Declercq, Carole Schwebel, Annabelle Stoclin, Marc Garnier, Benjamin Madeux, Stéphane Gaudry, Karine Bailly, Christian Lamer, Philippe Aegerter, Christine Rieu, Khaoussou Sylla, Bruno Lucas, Tarek Sharshar
Journal: The Lancet Respiratory Medicine (2021)
Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data
Authors: Julia Driessen, Fer de Wit, Alex F. Herrera, Pier Luigi Luigi Zinzani, Ann S. LaCasce, Craig H. Moskowitz, Ramon Garcia-Sanz, Peter D. Cole, Michael Fuchs, Horst Mueller, Peter Borchmann, Heiko Schöder, Josée M Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten
Journal: Blood (2021)
DNMT3A with Leukemia-Associated R882 Mutations Promotes Fitness Advantage through Functional Heterogeneity within HSCs
Authors: Zachary Zaroogian, Chamara Gunaratne, Daniil Shabashvili, Cassandra Berntsen, Yang Feng, Kartika Venugopal, Santhi Pondugula, Olga A Guryanova
Journal: Blood (2021)
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with <i>TP53</i> mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Authors: David A. Sallman, Rami S. Komrokji, Amy E. DeZern, Marie Sebert, Guillermo Garcia-Manero, Ramy Rahmé, David P. Steensma, Jacqueline Lehmann che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Kendra Sweet, Odile Beyne Rauzy, Andrew T. Kuykendall, Christian Recher, Amy F McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Celine Berthon, Najla Al Ali, Bruno Quesnel, Eric Padron, Greg Korbel, Eyal C. Attar, Hagop Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau
Journal: Blood (2021)
<i>IDH</i> Mutations Are Enriched in Myelodysplastic Syndromes Patients with Severe Neutropenia: A Potential Targeted Therapy
Authors: Rami S. Komrokji, Najla Al Ali, Onyee Chan, Andrew T. Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Journal: Blood (2021)
Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation
Authors: Shanee Chung, Jennifer White, Cynthia L. Toze, Heather J. Sutherland, David Sanford, Judith Anula Rodrigo, Thomas J. Nevill, Sujaatha Narayanan, Stephen H. Nantel, Florian Kuchenbauer, Kevin A. Hay, Donna L. Forrest, Yasser Abou Mourad, Kevin Song, Maryse Power
Journal: Blood (2021)
Parathyroid Hormone Resistance and Autoantibodies to the PTH1 Receptor
Authors: Adel Mandl, Peter D. Burbelo, Giovanni Di Pasquale, You Sher Tay, James Welch, Michail S. Lionakis, Sergio D. Rosenzweig, Meryl A. Waldman, Blake M. Warner, Brian Walitt, Michael T. Collins, James E. Balow, John A. Chiorini, William F. Simonds, Sunita K. Agarwal, Jenny E. Blau, Lee S. Weinstein
Journal: New England Journal of Medicine (2021)

We describe two cases of acquired parathyroid hormone (PTH) resistance consequent to the development of serum PTH type 1 receptor (PTH1R) autoantibodies, which block PTH binding and signaling. Both cases were associated with other autoimmune manifestations, and one case was associated with atypical membranous glomerulonephritis. In vitro binding and signaling assays identified the presence of PTH1R-blocking IgG autoantibodies, which were not present in serum samples from patients with other renal or autoimmune disorders. (Funded by the Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases and others.).
HMGA2 Maintains Hematopoietic Stem Cell Via Pleiotropic Regulation of the Transcription in Stress Conditions
Authors: Sho Kubota, Yuqi Sun, Jie Bai, Takako Yokomizo-Nakano, Mariko Morii, Takako Ideue, Motomi Osato, Terumasa Umemoto, Kimi Araki, Goro Sashida
Journal: Blood (2021)
Covid-19: Germany’s doctors call for clear rules to “break chains of infection” as cases soar
Authors: Ned Stafford
Journal: BMJ (2021)

Covid-19: Germany's doctors call for clear rules to "break chains of infection" as cases soar Ned StaffordPoliticians and doctors in Germany have called for urgent action to control the spread of covid-19 after a record number of cases were reported on 11 November.